Scholarlink

Background <p>Precise, early diagnosis of liver metastasis improves clinical outcomes in patients with pancreatic cancer. While gadoxetate sodium-enhanced magnetic resonance imaging (EOB–MRI) may offer additional benefits in detecting liver metastases in patients with pancreatic cancer, it is still unclear whether the addition of this imaging modality to contrast-enhanced computed tomography (CE–CT) confers clinical benefits regarding prognosis and access to appropriate treatments.&#xa0;The objective is to evaluate the treatment pathway of patients with or without EOB–MRI after a pancreatic cancer diagnosis and examine whether the addition of EOB–MRI is associated with improved survival.</p> Methods <p>A retrospective cohort study was conducted using a Japanese hospital-based administrative database. Patients aged ≥ 18&#xa0;years and diagnosed with pancreatic cancer between 2011 and 2021 with any record of CE–CT or MRI were included.&#xa0;Patients&#xa0;were&#xa0;stratified based on a record of EOB–MRI (EOB–MRI vs. non-EOB–MRI).&#xa0;Main outcomes&#xa0;were treatment pathway and overall survival&#xa0;(OS).&#xa0;OS&#xa0;was compared between the EOB–MRI and non-EOB–MRI groups using Cox proportional hazard regression models in the propensity-score-matched cohort.</p> Results <p>A total of 39,624 patients were included. The proportion of neoadjuvant chemotherapy increased to 13.4% during recent years (2019–2021) in the EOB–MRI group versus 7.8% in the non-EOB–MRI group. Significantly longer&#xa0;OS&#xa0;in the matched cohort was observed (HR [95% CI] = 0.88 [0.83–0.94]) in the EOB–MRI group (1,442&#xa0;days [1275–1604]) versus the non-EOB–MRI group (1,293&#xa0;days [1187–1440]).</p> Conclusions <p>The addition of EOB–MRI was associated with increased survival times in patients with pancreatic cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical significance of gadoxetate sodium-enhanced MRI for detecting liver metastasis in patients with pancreatic cancer: decadal real-world data analysis in Japan

  • 期刊论文

  • 发表日期：

    2026年5月4日

查看全文
  • Atsushi Oba,
  • Tomoyuki Taguchi,
  • Naoto Fujikawa,
  • Suguru Okami,
  • Takashi Tsuji,
  • Alexander Michel,
  • Satoshi Goshima

摘要

Background

Precise, early diagnosis of liver metastasis improves clinical outcomes in patients with pancreatic cancer. While gadoxetate sodium-enhanced magnetic resonance imaging (EOB–MRI) may offer additional benefits in detecting liver metastases in patients with pancreatic cancer, it is still unclear whether the addition of this imaging modality to contrast-enhanced computed tomography (CE–CT) confers clinical benefits regarding prognosis and access to appropriate treatments. The objective is to evaluate the treatment pathway of patients with or without EOB–MRI after a pancreatic cancer diagnosis and examine whether the addition of EOB–MRI is associated with improved survival.

Methods

A retrospective cohort study was conducted using a Japanese hospital-based administrative database. Patients aged ≥ 18 years and diagnosed with pancreatic cancer between 2011 and 2021 with any record of CE–CT or MRI were included. Patients were stratified based on a record of EOB–MRI (EOB–MRI vs. non-EOB–MRI). Main outcomes were treatment pathway and overall survival (OS). OS was compared between the EOB–MRI and non-EOB–MRI groups using Cox proportional hazard regression models in the propensity-score-matched cohort.

Results

A total of 39,624 patients were included. The proportion of neoadjuvant chemotherapy increased to 13.4% during recent years (2019–2021) in the EOB–MRI group versus 7.8% in the non-EOB–MRI group. Significantly longer OS in the matched cohort was observed (HR [95% CI] = 0.88 [0.83–0.94]) in the EOB–MRI group (1,442 days [1275–1604]) versus the non-EOB–MRI group (1,293 days [1187–1440]).

Conclusions

The addition of EOB–MRI was associated with increased survival times in patients with pancreatic cancer.